EP4353230A3 — Solid state forms of asciminib and process for preparation thereof
Assigned to Teva Pharmaceuticals International GmbH · Expires 2024-06-19 · 2y expired
What this patent protects
The present disclosure encompasses solid state forms of Asciminib and salts thereof, in embodiments crystalline polymorphs of Asciminib and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
USPTO Abstract
The present disclosure encompasses solid state forms of Asciminib and salts thereof, in embodiments crystalline polymorphs of Asciminib and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
Drugs covered by this patent
- Scemblix (ASCIMINIB HYDROCHLORIDE) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.